News

Vibativ is a bactericidal, once-daily antibiotic with in vitro potency and a dual mechanism of action against Gram-positive bacteria. Russian pharmaceutical firm R-Pharm will be responsible to market

The company said that the EORA program was awarded a Blueprint Neurotherapeutics (BPN) grant from the National Institutes of Health (NIH) to develop the program from the preclinical

The company has completed enrollment and dosing in a Phase I clinical trial of Aerucin and the results are expected to be reported in the fourth quarter of

LIPO-202 is an injectable formulation of salmeterol xinafoate, a long-acting ß2-adrenergic receptor agonist used in several FDA-approved drugs, including Advair, which is indicated to treat asthma. In the

This US based trial will be conducted under the active investigational new drug (IND) application on file with the US Food and Drug Administration (FDA). Around 180 patients

Ozoralizumab includes two nanobodies targeting TNFa, which are linked to a nanobody that binds to human serum albumin, extending the drug’s half-life and improving its distribution to inflamed

In addition to this non-contingent license payment of $120.0 million, as previously announced, FibroGen received a $15.0 million milestone payment from AstraZeneca during the second quarter of 2015

The collaboration is designed to identify combination regimens that provide synergies in efficacy and durability in patients with metastatic cutaneous and uveal melanomas. IMCgp100 is Immunocore’s lead T

This single ascending dose trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742 in healthy human volunteers, with results expected in the second half of 2015.